Skip to main content
. Author manuscript; available in PMC: 2017 Sep 26.
Published in final edited form as: Future Oncol. 2015;11(6):909–922. doi: 10.2217/fon.14.276

Table 3.

Phase II clinical trials of bevacizumab in cervical cancer.

Study Drug n Eligibility Pathology OS
(months)		 PFS
(months)		 RR
(%)		 Grade 3–4 AEs Ref.
Monk et al. Bevacizumab 15 mg/kg Q3w 46 Second line (74%); third line (26%); GOG PS 0–2 Squamous, adenosquamous 7.3 3.4 35 HTN (15%); thromboembolism (11%); anemia (4%); vaginal bleeding (2%); neutropenia (2%); pain (13%); GI (8.7%); cardiovascular (4.3%); pulmonary (2%); fistula (2%) [60]
Schefter et al. Cisplatin 40 mg/m2+ radiation therapy + brachytherapy + bevacizumab 10 mg/kg Q2w for three cycles 49 Untreated patients with st age 1B-3B cervical cancer Squamous (80%) NR NR NR No treatment related SAEs; hematalogic AE 80% [58]
Zighelboim et al. Cisplatin 50 mg/m2 day 1 + topotecan 0.75 mg/m2 days 1, 2, 3 + bevacizumab 15 mg/kg day 1 Q3w 27 First recurrence; GOG PS 0–1 Squamous (67%), adenocarcinoma (33%) 13.2 7.1 35 Leukopenia (74%); neutropenia (56%); thrombocytopenia (81%); anemia (63%); GI (19%); pain (33%); metabolic (48%); infection (19%) [61]

AE: Adverse event; GI: gastrointestinal; GOG: Gynecologic Oncology Group; HTN: Hypertension; NR: Not reported; OS: Overall survival; PFS: Progression-free survival; PS: Performance status; Q3w: Every 3 weeks; RR: Response rate; SAE: Serious adverse event.